AGA is seeking public comment on a new guideline for the management of moderate to severe ulcerative colitis (UC), which addresses the medical management of adult outpatients with moderate to severe UC, as well as the medical management of adult hospitalized patients with acute severe ulcerative colitis (ASUC). This guideline focuses on immunomodulators, biologics and small molecules for induction and maintenance of remission (for moderate to severe UC) and decreasing the risk of colectomy (for ASUC). Unless otherwise specified, it does not present separate recommendations for induction and maintenance of remission.
Review and submit feedback by April 24
AGA is seeking public comment on the clinical practice guideline, clinical decision support tools and technical review for the management of moderate to severe UC. Please review the following documents:
Submit your comments by completing this survey. The public comment period ends at noon EDT on Wednesday, April 24.
Learn more about AGA’s clinical practice guidelines.
